Conference Posters

Posters being presented at our 2011 conference

Back to the main conference page

Host-Pathogen Interactions

Presenting Author Institution Title
Copland Alastair University College London, UK Neisseria meningitidis serogroup B targets human dendritic cells to modify T helper cell responses in vitro
Davenport Victoria University of the West of England, Bristol, UK Anti-inflammatory and cyto-protective properties of commensal Neisseriae
Pike Andrew University of Sheffield Medical School,Sheffield, UK Role of factor H binding protein (fHbp) in intracellular survival of Neisseria meningitidis after phagocytosis by human macrophages
Rodrigues Charlene St Mary’s Campus, Imperial College London, UK. Complement factor H genotype and protein levels associated with the clinical sepsis phenotype in children with meningococcal disease
Wright Victoria Paediatrics, Imperial College London, UK Gene Expression in relation to severity of Meningococcal Disease
Zhang Lan Merck, West Point, PA, USA Meningococcal surface protein mutations that disrupt human serum protein binding - a strategy for enhanced immunogen design

Epidemiology and Surveillance

Presenting Author Institution Title
Bukovski Suzana University Hospital for Infectious Diseases “Dr Fran Mihaljević” Zagreb, Croatia 2011 - Invasive Bacterial Diseases caused by N.meningitidis, H.influenzae, S. pneumoniae and L.monocytogenes at University Hospital for Infectious Diseases “Dr Fran Mihaljević” Zagreb, Croatia
Collard Jean-Marc Centre de Recherche Médicale et Sanitaire (CERMES), Niamey, Niger Determination of Pneumococcal Serotypes in Meningitis Cases in Niger, 2003 – 2011.
Crowcroft Natasha Public Health Ontario, Toronto, Canada Epidemiology of Serogroup B Invasive Meningococcal Disease in Ontario, Canada, 2000-2010
Gray Steve Health Protection Agency Meningococcal Reference Unit, Manchester, UK. The Epidemiology And Surveillance Of Meningococcal Disease In England And Wales.
Guiver Malcolm Health Protection Agency Meningococcal Reference Unit, Manchester, UK. Modifications To A Published Ctra Pcr Assay For The Improved Non-Culture Confirmation Of Meningococcal Disease In England And Wales.
Heuberger Sigrid National Reference Centre for Meningococci, Pneumococci and H.influenzae, Austrian Agency for Health and Food Safety, Austria Austria 2005-2010, Epidemiology of Invasive Pneumococcal Disease
Irving Tom University of Bristol, UK Approaches to modelling serogroup A meningococcal disease in Africa
Koroleva Irina Central Research Institute of Epidemiology, Moscow, Russia Epidemiology of Invasive Meningococcal Disease in Moscow, 2005-2010
McDonald Eisin Health Protection Scotland, Glasgow, Scotland The epidemiology of invasive meningococcal disease in Scotland 1999-2010.
Okike Ifeanyichukwu Child Health and Vaccine Institute, St George’s, University of London Bacterial meningitis in babies 0-90 days of age: A UK and Republic of Ireland prospective study.
Rots Nynke National institute of Public Health and the Environment, Bilthoven, Continuing increase in 19A and 6C serotype carriage in children after the introduction of PCV-7 in the Netherlands
Trotter Caroline University of Bristol, Bristol, UK Seroprevalence of serum bactericidal antibodies against group W135 and Y meningococci in England in 2009

Clinical Diagnosis, Treatment and Sequalae

Presenting Author Institution Title
Archer Jane Peterborough City Hospital, UK Oculomotor nerve palsy secondary to childhood bacterial meningitis: a systematic literature review of outcome and management effectiveness.
Barnes James Bristol Royal Hospital for Sick Children, Bristol, UK Angular deformity of the ankle with distal fibula sparing following meningococcal septicaemia.
Barnes James Bristol Royal Hospital for Sick Children, Bristol, UK Distal tibial growth arrest following Meningococcal septicaemia; Management and outcome in a series of seven ankles
Clancy Eoin National University of Ireland, Galway, Ireland Development of a tmRNA based NASBA Assay for the Detection of Neisseria meningitidis 
Clark Laura University of Bristol & Meningitis Research Foundation, Bristol, UK Meeting the health, social and educational needs of children who have survived meningitis and septicaemia: the parents perspective
Desmond, Nicola Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, Malawi Recognition and action to tackle acute bacterial meningitis in urban Blantyre, Malawi
Deutch Susanna Aarhus University Hospital, Aarhus, Denmark Bacterial Meningitis In Adults And Dexamethasone, A 10 Year Review From Aarhus, Denmark
Fleming Susannah University of Oxford, UK How sick is this child? Predicting serious infections using four vital signs
Fuller Robert University of Liverpool, UK Purpura Fulminans in Childhood Meningococcal Septicaemia
Lee Lucia Center for Biologics Evaluation and Research, Food and Drug Administration, USA Risk Evaluation and Plan to Prevent Meningococcal Infections in Eculizumab-treated Individuals
Seleem Wail Hamad Medical Corporation, Doha, Qatar In suspected cases of meningitis, do we need a CT scan before doing a lumbar puncture?

Public Health Management

Presenting Author Institution Title
Ashton Charlotte, Walsh Barry Health Protection Agency, London, UK Meningitis in the Facebook generation: Public health out of hours management of a complex meningitis case in a teenager
Halewood Anne HPA, Newcastle upon Tyne, UK Investigation of the uptake of chemoprophylaxis by contacts of cases of meningococcal disease in the North East of England

Vaccine Discovery and Vaccinology

Presenting Author Institution Title
Allen Lauren Health Protection Agency, Salisbury, UK Correlation of a high-throughput flow cytometric antibody-mediated membrane attack complex assay with the serum bactericidal assay
Anderson Annaliesa Pfizer Vaccine Research, New York, USA Evaluation of the Impact of fHBP Vaccines on IMBD and N. meningitidis Carriage Isolates
Bidmos Fadil University of Leicester, UK Examination of two meningococcal surface proteins as potential vaccine targets
Boccadifuoco Giuseppe Novartis Vaccines and Diagnostics, Siena, Italy Estimating The Potential Strain Coverage In Europe Of A Multicomponent Vaccine Targeting Serogroup B Meningococci
Bottomley Matthew J Novartis Vaccines and Diagnostics, Siena, Italy The application of Structural Vaccinology in the development of a meningococcal antigen inducing broad protective immunity
Claus Heike University of Würzburg, Germany Potential strain coverage of a multi-component meningococcus B vaccine in Germany and the Czech Republic
Comanducci Maurizio Novartis Vaccines and Diagnostics, Siena, Italy Antigen Diversity Of The 4CMenB Vaccine Components In Serogroup B Meningococcal Patient Isolates From Five European Countries
Crowcroft Natasha Public Health Ontario, Toronto, Canada Serogroup C invasive meningococcal disease (IMD) in Ontario, Canada, 2000-2010: vaccine impact assessment
Dull Peter Novartis Vaccines & Diagnostics, Cambridge, MA, USA. Immunogenicity of an Investigational Multicomponent Meningococcal Serogroup B (4cmenb) Vaccine in Healthy Adolescents Following 1, 2 or 3 Doses
Dull Peter Novartis Vaccines & Diagnostics, Cambridge, MA, USA. Evaluation of antibody persistence and response to a MenACWY-CRM conjugate vaccine (Menveo®) booster in adolescents five years after receiving MenACWY-CRM or a quadrivalent meningococcal polysaccharide vaccine (Menomune®) assessed by serum bactericidal assays using rabbit complement (rSBA)
Dull Peter Novartis Vaccines & Diagnostics, Cambridge, MA, USA. Pivotal Safety And Immunogenicity Of An Investigational Quadrivalent Meningococcal Conjugate Vaccine (MenACWY-CRM; Menveo®) In Infants In The United States And Latin America
Dull Peter Novartis Vaccines & Diagnostics, Cambridge, MA, USA. Immunogenicity of Meningococcal Quadrivalent (MenACWY-CRM197) Conjugate and Measles-Mumps-Rubella-Varicella (MMRV) Vaccines when Administered Concomitantly in 12 Month-Old Toddlers
Findlow Jamie Health Protection Agency, Manchester, UK Potential Coverage Of English And Welsh Capsular Group B Isolates By An Investigational Meningococcal Group B Vaccine (4cmenb)
Gossger Nicoletta University of Oxford, Oxford, UK Immunogenicity Of An Investigational Multicomponent Meningococcal Serogroup B Vaccine (4CMenB) Administered With Or Without Routine Infant Vaccinations In Different Schedules
Gossger Nicoletta University of Oxford, Oxford, UK Reactogenicity And Safety Of Multicomponent Meningococcal Serogroup B Vaccine (4CMenB) Administered With Or Without Routine Infant Vaccinations In Different Schedules
Hung Miao-Chiu University of Southampton Faculty of Medicine, Southampton, UK The Neisseria meningitidis-macrophage infectivity potentiator (MIP) protein induces cross-strain serum bactericidal activity and is a potential serogroup B vaccine candidate
Jones Hannah University College London, UK Using lipooligosaccharide modified natural outer membrane vesicles to target meningococcal antigens to human dendritic cells
Kaaijk Patricia National Institute for Public Health and the Environment (RIVM), The Netherlands; Preclinical safety and immunogenicity evaluation of a new generation nonavalent PorA OMV vaccine against serogroup B meningococcus
Kristiansen Paul A Norwegian Institute of Public Health (NIPH), Oslo, Norway Impact of a New Serogroup A Meningococcal Conjugate Vaccine, MenAfriVacTM, on Carriage of Serogroup A Neisseria meningitidis: Preliminary results from Burkina Faso
Medini Duccio Novartis Vaccines and Diagnostics, Siena, Italy Meningococcal Antigen Typing System (MATS) was a conservative estimate of killing when confirmed in a  serum bactericidal assay using human complement (hSBA)
Pallaoro Michele Novartis Vaccines and Diagnostics, Siena, Italy Inducing cross protection within fHBP variants
Rajam Gowrisankar CDC, Atlanta, USA Development Of A Multiplex Bead Based Meningococcal Antigen Typing System (BMATS)
Romeu Belkis Finlay Institute, Havana, Cuba. AFCo1 provides nasal adjuvant activity against capsular polysaccharides of Neisseria meningitidis serogroup C and Salmonella Typhi
Romeu Belkis Finlay Institute, Havana, Cuba. From Neisseria meningitidis serogroup B vaccine to Potent Adjuvants
Serruto Davide Novartis Vaccines and Diagnostics, Siena, Italy Evaluation of the immunological properties of the Neisserial Heparin Binding Antigen (NHBA)
Thomas Steve Health Protection Agency, Salisbury, UK Development of a flow cytometric antibody-mediated complement deposition assay for Group B Streptococcus

Back to the main conference page